Market comparative analysis of adalimumab injection prices

Adalimumab (Adalimumab), as the world's first approved anti-TNF-α monoclonal antibody, has been the core biological agent for the treatment of rheumatic immunity and intestinal inflammatory diseases since its inception. As the patents of this drug have expired in many countries around the world in recent years, generic drugs (biosimilars) have been launched one after another, and the price system has also undergone significant changes. Especially after the Chinese market has gradually been included in the medical insurance catalog, the price has been significantly reduced, and patient accessibility has been significantly improved.

Currently in the domestic market, the original drugHumira and a number of domestic biosimilar drugs such as Yuemu and Anbainuo have been approved for marketing and are widely used in the treatment of various autoimmune diseases such asrheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, atopic dermatitis, Crohn's disease, etc. After medical insurance negotiation, the price of a single dose of adalimumab (40mg/0.4ml) has been reduced to about RMB 1,000, which greatly reduces the burden on patients.

In overseas markets, such as the United States or Europe, the market price of original drugs is generally higher. For example, in the United States, the retail price of 40mg/0.4ml Humira is close to US$5,000, equivalent to more than 30,000 yuan, mainly due to differences in pricing mechanisms, market protection periods, and commercial insurance mechanisms. However, as the U.S. FDA has approved the marketing of several biosimilar drugs (such as Amjevita, Hyrimoz, etc.), prices have become looser, especially in some medical insurance countries. Through centralized procurement and price negotiations, the price of adalimumab drugs has gradually become the same as or even lower than domestic prices.

It should be pointed out that although the price of generic drugs is lower, their therapeutic effect and safety must be verified by bioequivalence and clinical consistency, and the safety of use is guaranteed. Some domestically produced versions have undergone strict quality review and have little difference in clinical effects from the original drugs.

Therefore, in the Chinese market, especially under the premise of medical insurance coverage, the economic pressure on patients to use adalimumab has been significantly reduced, and market competition will continue to drive its price stabilization, which is expected to further improve treatment compliance and long-term efficacy of patients with chronic diseases.

Reference materials:https://www.drugs.com/adalimumab.html